Acute Leukemia News
- No Survival Gain From High-Dose Cytarabine Consolidation in AML
- ASCO 2022 Forget Moonshot: Cancer Patients Right Now Need 'Groundshot'
- EHA 2022 Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML
- EHA 2022 Similar Survival, Less Toxicity With Decitabine vs Chemo in AML
- AYA Leukemia Survivors: 'Cure Is Not Enough'
- Venetoclax Add-On Promising in Newly Diagnosed AML
- Lab Algorithm Cancels Same-Day Redundant Orders Automatically
- Alert EMA Begins Review of Rucaparib After Finding of Shorter Survival
- Inhibiting the LSD1 Enzyme Renders Some Leukemia Cells Sensitive to TKI Treatment
- Adding Ivosidenib to Azacitidine Improves Survival in IDH1-Mutated AML
- COVID Vaccine Response Varies by Blood Cancer Type, Treatment
- AACR 2022 Biomarker Predicts Nonresponse to CAR T in Pediatric ALL
- Bridging Oceans, Docs Rally to Save a Ukrainian Cancer Patient
- Newly Characterized Mutation May Define Leukemia Subtype in Kids
- CROI 2022 Third Transplant Patient Cured of HIV Marks Important Firsts
- Venetoclax Add-On Improves Complete Remission in AML
- Blast Counts Not Enough to Distinguish MDS From AML, Experts Say
- Pandemic-Fueled Shortages of Home Health Workers Strand Patients Without Necessary Care
- Alert EMA Gives Green Light to New CAR-T Cell Therapy
- Surrogate Endpoints Acceptable in AML Trials, Says FDA